Crispr Therapeutics AG (NASDAQ:CRSP) was the recipient of a large decline in short interest in November. As of November 29th, there was short interest totalling 3,620,000 shares, a decline of 34.9% from the November 14th total of 5,560,000 shares. Approximately 10.6% of the shares of the company are sold short. Based on an average daily trading volume, of 914,900 shares, the short-interest ratio is currently 4.0 days.
Shares of CRSP stock traded down $0.48 during mid-day trading on Thursday, reaching $66.75. The stock had a trading volume of 1,295,791 shares, compared to its average volume of 716,646. Crispr Therapeutics has a 1-year low of $24.84 and a 1-year high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market cap of $3.75 billion, a price-to-earnings ratio of -19.40 and a beta of 3.31. The business’s fifty day moving average is $63.87 and its 200-day moving average is $50.25.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. On average, analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current year.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Roth Capital upped their price target on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Goldman Sachs Group increased their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Finally, Needham & Company LLC reissued a “buy” rating and set a $84.00 target price on shares of Crispr Therapeutics in a research note on Monday. Two analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $71.38.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at $412,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,118 shares of company stock worth $3,620,760. Insiders own 21.40% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Nikko Asset Management Americas Inc. boosted its position in Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after acquiring an additional 906,006 shares during the last quarter. Orbimed Advisors LLC acquired a new stake in shares of Crispr Therapeutics in the 3rd quarter worth $21,167,000. Price T Rowe Associates Inc. MD increased its stake in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after acquiring an additional 121,176 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after acquiring an additional 116,540 shares during the period. Finally, Balyasny Asset Management LLC purchased a new position in shares of Crispr Therapeutics during the 2nd quarter worth $5,165,000. 49.82% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Penny Stocks, What You Need To Know
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.